On August 8, the U.S. Food and Drug Administration (FDA) approved Poteligeo (mogamulizumab-kpkc) injection for IV use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. These are two rare, hard-to-treat types of non-Hodgkin lymphoma.
Read more via U.S. Food and Drug Administration.
